Vivek Subbiah

Specialty: Precision Oncology - Rare cancer trials

Location: Global

Tier: ELITE

H-Index: 110

Years Active: 0

Hospital Affiliations

• MD Anderson (India-origin) - Faculty

Key Publications

1. "The next generation of evidence-based medicine." - Nat Med (2023)
2. "Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial." - Lancet Oncol (2020)
3. "Variant allele frequency: a decision-making tool in precision oncology?" - Trends Cancer (2023)
4. "Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial." - Nat Med (2023)
5. "Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial." - Lancet Oncol (2022)

Knowledge Graph Relationships

Vivek Subbiah is a Precision Oncology - Rare cancer trials specialist affiliated with MD Anderson (India-origin). Authored 5 scholarly articles.